Yamamoto Kengo, Kurioka Takaomi, Ohki Motofumi, Sano Hajime, Yamashita Taku
Department of Otorhinolaryngology, Kitasato University Medical Center, Kitamoto, Japan.
Department of Otorhinolaryngology-Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Front Neurol. 2023 Apr 28;14:1167128. doi: 10.3389/fneur.2023.1167128. eCollection 2023.
Some idiopathic sudden sensorineural hearing loss (ISSHL) cases experience repetitive systemic corticosteroid treatment, but studies focusing on repetitive systemic corticosteroid administration have not been reported. Thus, we investigated the clinical characteristics and usefulness of repetitive systemic corticosteroid treatment in ISSHL cases.
We reviewed the medical records of 103 patients who received corticosteroids only in our hospital (single-treatment group), and 46 patients who presented at our hospital after receiving corticosteroids in a nearby clinic and were subsequently treated with corticosteroids again in our hospital (repetitive-treatment group). Clinical backgrounds, hearing thresholds, and hearing prognosis were assessed.
The final hearing outcomes were not different between the two groups. Further, in the repetitive-treatment group, statistical differences were found between the good and poor prognosis groups in the number of days to start corticosteroid administration ( = 0.03), the dose of corticosteroid ( = 0.02), and the duration of corticosteroid administration ( = 0.02) at the previous facility. Multivariate analysis revealed a significant difference in the dose of corticosteroids administered by the previous clinic ( = 0.004).
The repetitive systemic corticosteroid administration might play a supplementary role in hearing improvement, and initial sufficient corticosteroid administration would lead to good hearing outcomes in an early phase of ISSHL.
一些特发性突发性感音神经性听力损失（ISSHL）病例接受了反复的全身皮质类固醇治疗，但尚未有专注于反复全身皮质类固醇给药的研究报道。因此，我们调查了反复全身皮质类固醇治疗在ISSHL病例中的临床特征和有效性。
我们回顾了仅在我院接受皮质类固醇治疗的103例患者（单次治疗组）以及在附近诊所接受皮质类固醇治疗后到我院就诊并随后在我院再次接受皮质类固醇治疗的46例患者（反复治疗组）的病历。评估了临床背景、听力阈值和听力预后。
两组的最终听力结果无差异。此外，在反复治疗组中，预后良好组和预后不良组在前一机构开始使用皮质类固醇的天数（=0.03）、皮质类固醇剂量（=0.02）和皮质类固醇给药持续时间（=0.02）方面存在统计学差异。多因素分析显示前一诊所给予的皮质类固醇剂量存在显著差异（=0.004）。
反复全身皮质类固醇给药可能在听力改善中起辅助作用，并且在ISSHL早期给予足够的初始皮质类固醇会带来良好的听力结果。
